An all oral antiemetic regimen for patients undergoing high-dose chemotherapy with peripheral blood stem cell transplant

Bone Marrow Transplantation

Volumn 20, Issue 6, 1997, Pages 473-478

  Frakes, L A ^a   Brehm, T L ^a   Kosty, M P ^a   Miller, W E ^a   McMillan, R L ^a   Mason, J ^a   Meisenberg, B R ^b,c  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

High dose chemotherapy; Nausea; Serotonin antagonists; Stem cell transplantation; Vomiting

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; ETOPOSIDE; GRANISETRON; PROCHLORPERAZINE; PROCHLORPERAZINE MALEATE; SEROTONIN ANTAGONIST; THIOTEPA;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; DRUG EFFICACY; DRUG SAFETY; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; STEM CELL TRANSPLANTATION; VOMITING;

EID: 0030800690     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700911     Document Type: Article

References (29)

1. Fetting JH, Grochow LB, Folstein MF et al. The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 1982; 66: 1487-1493.
2. Antman K, Eder JP, Elias A et al. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience. Cancer Treat Rep 1987; 71: 119-125.
3. Navari RM, Plezia P, Kaplan HG et al. Single-dose, double-blind, multicenter study evaluating the efficacy and safety of intravenous (IV) granisetron in the prevention of cisplatin-induced nausea and vomiting. Proc Am Soc Clin Oncol 1993; 12: (Abstr. 1511).
4. Chevallier B. Efficacy and safety of granisetron compared with high-dose metoclopromide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 1990; 26 (Suppl. 1): S33-S36.
5. Aguara ED, Cleveland Brown M, Schaffer R et al. Antiemetic efficacy and pharmacokinetics of intravenous ondansetron infusion during chemotherapy conditioning for bone marrow transplant. Bone Marrow Transplant 1995; 16: 213-222.
6. Bosi A, Buidi S, Messori A et al. Ondansetron versus chlorpromazine for preventing emesis in bone marrow transplant recipients: a double-blind randomized study. J Chemother 1993; 5: 191-196.
7. Barbounis V, Koumakis G, Vassilomanolakis M et al. A phase II study of ondansetron as antiemetic prophylaxis in patients receiving high-dose polychemotherapy and stem cell transplantation. Support Care Cancer 1995; 3: 301-306.
8. Lopez-Martin JA, Martin M, Casado A et al. 'Control' of high-dose chemotherapy-induced emesis: one more reason for continuing antiemetic research. Support Care Cancer 1995; 3: (Abstr. 34).
9. Okamoto S, Takahashi S, Tanosaki R et al. Granisetron in the prevention of vomiting induced by conditioning for stem cell transplantation: a prospective randomized study. Bone Marrow Transplant 1996; 17: 679-683.
10. Or R, Drakos P, Nagler A et al. The antiemetic efficacy and tolerability of tropisetron in patients conditioned with high-dose chemotherapy (with and without total body irradiation) prior to bone marrow transplantation. Support Care Cancer 1994; 2: 245-248.
11. Blower P. A pharmacologic profile of oral granisetron (Kytril tablets). Semin Oncol 1995; 22: 3-5.
12. Heron JF, Goedhals L, Jordaan JP et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopromide plus dexamethasone in prevention of cisplatin-induced emesis. Ann Oncol 1994; 5: 579-584.
13. Hesketh PJ, Harvey WH, Harker WG et al. A randomized double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. J Clin Oncol 1994; 12: 596-600.
14. The Italian Group for Antiemetic Research. Dexamethasone, granisetron or both for the prevention of nausea and vomiting during chemotherapy for cancer. New Engl J Med 1995; 332: 1-5.
15. Hesketh PJ, Gandara DR, Hainsworth J et al. Addition of the dopamine D2 antagonist prochlorperazine to granisetron/ dexamethasone: improved control of acute emesis from high dose cisplatin. Proc Am Soc Clin Oncol 1996; 15: (Abstr. 1754).
16. Matsui K, Fukuoka M, Takada M et al. Randomized trial for the prevention of delayed emesis in patients receiving high-dose cisplatin. Br J Cancer 1996; 73: 217-221.
17. DelFavero A, Roila F, Basurto C et al. Assessment of nausea. Eur J Clin Pharmacol 1990; 38: 115-120.
18. Tonato M, Roila F, Del Favero A, Ballatori E. Methodology of trials with antiemetics. Support Care Cancer 1996; 4: 281-286.
19. Krasnow S. Problems in antiemetic trial design and interpretation. Oncology 1989; 4: 5-10.
20. Roila F, Tonato M, Basurto C et al. Antiemetic activity of high doses of metoclopramide combined with methylpredniso-lone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5: 141-149.
21. Meisenberg B, Gollard R, Brehm T et al. Prophylactic antibiotics eliminate bacteremia and allow safe outpatient management following high-dose chemotherapy and autologous stem cell rescue. Support Care Cancer 1996; 4: 364-369.
22. Gilbert CJ, Petros WP, Cavanaugh C et al. Influence of ondansetron (OND) on the pharmacokinetics (PK) of high dose cyclophosphamide (CPA). Proc Ann Meet Am Soc Clin Oncol 1995; 14: A931.
23. Rinehart J, Keville L, Measel J et al. Corticosteroid alteration of a carboplatin-induced hematopoietic toxicity in a murine model. Blood 1995; 86: 4493-4499.
24. Navari R, Madajewicz S, Anderson N et al. Oral ondansetron effectively control cisplatin induced delayed emesis. Proc Am Soc Clin Oncol 1995; 14: (Abstr. 1720).
25. Rittenburg CN, Gralla RJ, Lettow LA et al. New approaches in preventing delayed emesis: altering the time of regimen initiation and use of combination therapy in 109 patient trial. Proc Am Soc Clin Oncol 1995; 526: (Abstr. 1731).
26. Kris MG, Pisters KM, Hinkley L. Delayed emesis following anticancer chemotherapy. Support Care Cancer 1994; 2: 297-300.
27. Kaye SB, Khayat D, Aapro M et al. Who should receive a 5-HT3 antagonist? Lancet 1992; 340: 1107-1108.
28. Carmichael J, Cantwell MBJ, Edwards CM et al. A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with antiemetic response. Cancer Chemother Pharmacol 1989; 24: 45-19.
29. Meisenberg BR, Miller WE, McMillan R et al. Outpatient high-dose chemotherapy with autologous stem-cell rescue for hematologic and nonhematologic malignancies. J Clin Oncol 1997; 15 11-17.